Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Fatty liver; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms E-LIFT
- 14 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 14 Jun 2017 Status changed from completed to active, no longer recruiting.
- 17 May 2017 Status changed from recruiting to completed.